# Errata

Validation of the

Medaka Multigeneration Test:

Integrated Summary Report

U.S. Environmental Protection Agency

Endocrine Disruptor Screening Program

Washington, D.C.

June 21, 2013

|

## Forward

A portion of the medaka data provided in the MMT ISR was originally analyzed using the

statistical package StatCHARRMS that was recently found to have an error in the one

- way

ANOVA module. In that module the replicate data was not considered in the statis tical analyses.

Thus, the statistical unit of analysis became the individual animal rather than the tank which

resulted in erroneous estimates of the following: biological variances, variances on effects due to

treatment, and variances on estimates of biol ogical means. It also introduces the possibility of

confounding treatment effects with possible tank effects. The analyses in the other two modules

of StatCHARRMS, a repeated measure ANOVA, and a pathology analysis module (RSCABS),

correctly incorporate the replicate structure of the test protocols. It should be noted that the re

coding of the one

- way ANOVA module in the open source ‘R’ version of StatCHARRMS being

developed by the Agency did not have this error and correctly identifies the statistical s ampling

unit as the tank, when specified, and not the individual organism.

Specifically, with respect to the MMT assay the StatCHARRMS error only affected the analysis

of AOP

- diagnostic endpoints measured in the subadults ( i.e., vitellogenin, secondary s ex

characters, and growth). The statistical analysis of adult endpoints such as the apical reproductive

endpoints, and endocrine diagnostic endpoints of AOPs such as pathology were not affected. The

statistics associated with the fecundity endpoint in all the MMT studies in the ISR were not

affected, and the power analysis and the MRT recommendations remain unaffected.

The MMT study data for the affected subadult endpoints of vitellogenin, secondary sex

characters, and growth from all the EPA

- and interl aboratory

- run tests, i.e. , octylphenol,

trenbolone, CMP, and vinclozolin, were reanalyzed to correct for the error. For the Japanese

MMT studies, i.e., 17β

- estradiol, o,p′

- DDT, 4

- t

- o ctylphenol, and tamoxifen, the original

statistical analysis of the subadu lt endpoints, as performed by the Japanese scientists, have been

incorporated into the corrected analysis.

The reanalysis most often resulted in no changes in the LOEC for any particular biomarker

measurement. However, the LOECs for some of the biomarker datasets, as a result of using the

aquarium as the unit of replication rather than the individual fish, did in fact change in the

reanalysis. The most common changes were to move the LOEC one treatment level higher. In a

few instances, the LOEC moved up more than one treatment level. A few decreases in the LOEC

level also occurred. These changes were observed in instances where the treatment means were

only slightly different (either higher or lower) than controls and no clear dose response was

evident.

The overall effect of data reanalysis indicates that while biological variability was somewhat

greater than indicated in the initial analyses for endpoints measured in subadult medaka, the

effects were minor, and do not impact assay performance, recomme nded endpoints to be

measured, or overall conclusions for each AOP, and the overall conclusions for each chemical

tested remain the same as in the ISR. Thus, while the reanalysis showed that the sensitivity of the

diagnostic endpoints was reduced in some cases, this reduction in sensitivity does not impact the

ability of the proposed testing protocols to detect endocrine mediated AOPs in the assays. The

utility of the assays for measuring dose

- response for endocrine mediated toxicities in EDSP Tier

2 testi ng is not affected. The EPA presentations on the MMT/MRT that will be given during the

SAP will acknowledge and address this issue.

The remainder of this erratum provides corrected summary tables and graphs for Appendices C

and H of the MMT ISR. All th e tables describing the LOECs for all the MMT endpoints have

### been modified to reflect the corrections to the subadult endpoints. For the EPA

- and

Interlaboratory

- run studies, the changes reflect the result of reanalysis of the endpoints data. For

the Japan ese MMT studies, (17β

- Estradiol, o,p′

- DDT, 4

- t

- Octylphenol and Tamoxifen from the

CERI and NIES labs respectively), the changes reflect the original Japanese

- p erformed statistical

analysis of the subadult endpoint data. The modified tables and graphs are attached to the end of

this Erratum.



### For each MMT, two tables are presented, the original table from either Appendix C or H

MMT Summary Reports of the MMT ISR, and the revised table. All revisions are

highlighted in yellow in the revised table. The graphs that were changed follow the

revised LOEC summary table for each test chemical. The changed locations for

significance indicators are specified in yellow boxes. A blank box indicates the removal

of the significance indicator; and a yellow box with an * in dicates the new LOEC.

A narrative describing the changes for each MMT chemical follow.

17β

- Estradiol CERI

There was only one change to the Summary LOEC table. In the original analysis the

LOEC for a reduction in the anal fin papillae in F 1 

### XY subadults was 2.8 ng/L. The

corrected LOEC for this endpoint, as specified in the statistical analysis preformed by the

Japanese, is two dose levels higher at 28 ng/ L.

4

- t

- Octylphenol MED

There were three changes in the Summary LOEC table for octylph enol MED. For anal fin

papillae, the LOEC for F 1 

### XY subadults changed by one treatment level from 25 μg/L to

51 μg/L. The LOECs for Vtg in both XY and XX in F 1 

### sub adults increased by a single

do s e level. The XY LOEC increased from 25 μg/L to 51 μg/L and the XX LOEC

increased from 51 μg/L to 102 μg/L, Finally for F 2 

### XX subadults, no LOEC cou ld be

determined > 51 μg/L, while in t he initial incorrect analysis

, it was 51 μg/L.

4

- t

- Octylphenol NIES

There were four changes in the Summary LOEC table for octylp henol NIES. Growth

LOECs in F 2 

### subadults were greater than the highest treatment level in this generation

( > 50 μg/L) as reported by the Japanese, instead of the incorrectly reported 25 μg/L for

weight and 6.25 μg/L for length. Anal fin papillae in F 2 

### XY fish also was initially

reported by the Japanese as greater than the highest treatment ( > 50 μg/L) instead of the

incorrectly calculated LOEC of 25 μg/L. Finally, the Vtg LOEC for F 1 

### XY fish changed

by one treatment level from 25 μg/L down to 12.5 μg/L.

o,p′

- DDT CERI

The LOECs, as reported by the Japanese, are identical to the Agency’s original calculated

LOECs.

4

- Chloro,3

- methyl phenol (CMP) MED

There were four changes in the Summary LOEC table for CMP MED. Three of them are

related to growth. The LO EC initially calculated for both weight and length of F 1 

### XY

fish was 165 μg/L (the second highest concentration tested) which was recalculated as

### being higher than 345 μg/L, the highest concentration tested. The initial analysis was

unable to determine a LOEC for length in F 2 

### XX fish, but the reanalysis calculated a

LOEC of 345 μg/L, the highest concentration tested. The last change was in the LOEC

for Vtg in F 2 

### XX fish, which initially was 345 μg/L, but upon reanalysis, the LOEC was

higher than the highe st concentration of 345 μg/L.

Tamoxifen NIES

There were 6 changes in the Summary LOEC table for tamoxifen NIES from those

erroneously calculated by the Agency and those initially reported by Japanese

researchers. Five of the six were in the growth para meters of weight and length in which

the initial LOEC was 20 μg/L and the reanalyzed LOEC was greater than the highest

concentration tested (20 μg/L). This situation was present in the following of F 1: 

### weight

for both XX and XY fish, and length for XY fis h. It was also present in the following of

F 2 

### : weight and length of XX fish. In addition, the LOEC for Vtg in F 2 

### XY fish increased

one treatment level from 1.3 μg/L to 2.5 μg/L.

Trenbolone MED

There were two changes in the Summary LOEC table for trenbo lone MED. The LOEC

for weight of XX fish in F 1 

### increased one treatment level from 32 ng/L to 84 ng/L.

Likewise, the LOEC for Vtg of XX fish in F 1 

### increased one treatment level from 32 ng/L

to 84 ng/L.

Prochloraz MED

There were four changes in the Summar y LOEC table for prochloraz MED. The LOEC

for F 2 

### XY weight changed from 5 μg/L (the lowest treatment) to greater than 25 μg/L, the

highest treatment. Similarly, the LOEC for F 2 

### XY length changed from 9 μg/L to greater

than 25 μg/L, the highest treatment. Also, the F 2 

### XX length changed one treatment level

from 9 μg/L to 5 μg/L. The means for these growth parameters were only slightly lower

than control means across all treatments, and there was little indication of a dose

response, therefore it is not su rprising that the reanalysis, at times, changed the LOECs

both multiple treatment levels. Finally the LOEC for anal fin papillae of F 2 

### XY fish

changed from greater than 25 μg/L (the highest concentration still with fish) to 9 μg/L

Vinclozolin MED

There w ere two changes in the Summary LOEC table for vinclozolin MED. The LOEC

for anal fin papillae of F 1 

### XY fish increased a single treatment level from 17 μg/L to 33

μg/L. The second change was in the LOEC for F 1 

### Vtg in XY fish which initially was

greater th an 136 μg/L (the highest concentration with fish present), but was recalculated

to be 33 μg/L.

Vinclozolin Lab 1

There were four changes in the Summary LOEC table for vinclozolin from Lab 1 of the

interlab. Of these, three of them involved growth para meters. Weight for both female

and male fish in F 1 

### initially had a LOEC of 82 μg/L, which upon reanalysis changed to a

LOEC greater than the highest concentration in the test, 197 μg/L. In addition, weight for

F 2 

### female fish was initially reported as 31 μg/L, but upon reanalysis changed to a

### LOEC greater than the highest concentration in the test, 197 μg/L. Lastly, the LOEC for

anal fin papillae in F 2 

### males increased two treatment levels from 5 μg/L to 31 μg/L.

Vinclozolin Lab 2

There were four chan ges in the Summary LOEC table for vinclozolin from Lab 2 of the

interlab. Weight for XY fish in F 1 

### initially had a LOEC of 62 μg/L, which upon

reanalysis changed to 360 μg/L, two treatment levels. Weight for XX fish in F 1 

### initially

had a LOEC of 12 μg/L, which upon reanalysis changed to 360 μg/L. Also, weight for

XY fish in F 2 

### initially had a LOEC of 62 μg/L, which upon reanalysis changed to 360

μg/L. Finally, Vtg in F 1 

### XX fish initially had a reported LOEC of 360 μg/L, but upon

reanalysis, the LOEC was in fact greater than 360 μg/L, the higher concentration tested.

Vinclozolin Lab 3

The LOECs, as calculated in the reanalysis, are identical to the Agency’s original

calculated LOEC s.

### Original Incorrect Summary Table (Table 1) for 17 β

- estradiol (Appendix H, page 6).

Corrected Summary Table (Table 1) for 17 β

- estradiol (Appendix H, page 6).

Any changes are highlighted with yellow boxes. E2 MMT LOEC Summary E2 (ng/L)

F1 F2 F0 F1 F2 Trt Conc S.D.

subadult subadult adult adult adult 1 0 0

XY XX XY XX XY XX XY XX XY XX 2 0.9 0.11

Weight LOEC>84 28↑ 3 2.8 0.35

Length LOEC>84 28↑ 4 8.9 1.04

Survival LOEC>84 LOEC>84 5 28 2.9

Hatch LOEC>84 28↓ 6 84 7.1

Papillae 2.8 ↓ 28↓ LOEC>84 28↓ LOEC>28

Vtg 28 ↑ 84 ↑ 28 ↑ 8.9 ↑ 28↑ LOEC>84 28↑ LOEC>84 28↑ LOEC>28

Gonad Phenotype 28 ↑ LOEC>84 28 ↑ LOEC>28 28↑ LOEC>84 28↑ LOEC>28

Fecundity LOEC>84 28↓ LOEC>28

Fertility LOEC>84 28↓ 28↓

Highest Conc 84 28 84 84 28

E2 MMT LOEC Summary E2 (ng/L)

F1 F2 F0 F1 F2 Trt Conc S.D.

subadult subadult adult adult adult 1 0 0

XY XX XY XX XY XX XY XX XY XX 2 0.9 0.11

Weight LOEC>84 28↑ 3 2.8 0.35

Length LOEC>84 28↑ 4 8.9 1.04

Survival LOEC>84 LOEC>84 5 28 2.9

Hatch LOEC>84 28↓ 6 84 7.1

Papillae 28↓ 28↓ LOEC>84 28↓ LOEC>28

Vtg 28 ↑ 84 ↑ 28 ↑ 8.9 ↑ 28↑ LOEC>84 28↑ LOEC>84 28↑ LOEC>28

Gonad Phenotype 28 ↑ LOEC>84 28 ↑ LOEC>28 28↑ LOEC>84 28↑ LOEC>28

Fecundity LOEC>84 28↓ LOEC>28

Fertility LOEC>84 28↓ 28↓

Highest Conc 84 28 84 84 28E2 F1 Subadult XY SSC CERI MMT

0 0.9 2.8 8.9 28 84

Concentration (ng/L) 0 20 40 60 80 100Anal Fin Papillae (#/fin)



# * * *

*

E2 F1 Subadult XY SSC CERI MMT

0 0.9 2.8 8.9 28 84

Concentration (ng/L) 0 20 40 60 80 100Anal Fin Papillae (#/fin)



# * * *

*

### Original Incorrect Summary Table (Table 1) for 4

- t

- octyphenol MED (Appendix H, page 25).

Corrected Summary Table (Table 1) for 4

- t

- octyphenol MED (Appendix H, page 25). 4tOP MMT LOEC Summary 4tOP (ug/L)

F1 F2 F0 F1 F2 Trt Conc S.D.

subadult (7 wpf) subadult (7 wpf) adult (15 wpf) adult (15 wpf) adult (15 wpf) 1 0 0

XY XX XY XX XY XX XY XX XY XX 2 6 0.6

Weight LOEC>102 LOEC> 102 LOEC>51 LOEC>51 LOEC>102 JT: 102 ↑ JT: 51 ↑ LOEC>102 LOEC>51 LOEC>51 3 13 1.5

Length LOEC>102 LOEC>102 LOEC>51 LOEC>51 LOEC>102 JT:102 ↑ JT: 13 ↑ LOEC>102 LOEC>51 LOEC>51 4 25 2.6

Survival LOEC>102 LOEC>51 LOEC>102 LOEC>102 LOEC>102 LOEC>102 LOEC>51 LOEC>51 5 51 5.6

Hatch 102 ↓ LOEC>51 6 102 8.5

Papillae D,JT: 25 ↓ LOEC>102 Du, JT: 13 ↓ LOEC>51 LOEC>102 LOEC>102 D,JT:102 ↓ LOEC>102 JT:13 ↓ LOEC>51

Vtg Du, JT: 25 ↑ Du, JT: 51 ↑ Du, JT: 25 ↑ JT : 51 ↑ D,JT: 51 ↑ LOEC>102 D, JT: 51 ↑ LOEC>102 51 ↑ LOEC>51

Gonad

Phenotype 25 ↑ LOEC>102 25 ↑ LOEC>51 LOEC>102 LOEC>102 13 ↑ LOEC>102 51 ↑ LOEC>51

Fecundity LOEC>102; trend ↓ 102 ↓ 51↓; not by wk

Fertility LOEC>102; trend ↓ 102 ↓ 51↓; e sp wk11

Highest

Conc 102 51 102 102 51

4tOP MMT LOEC Summary 4tOP (ug/L)

F1 F2 F0 F1 F2 Trt Conc S.D.

subadult (7 wpf) subadult (7 wpf) adult (15 wpf) adult (15 wpf) adult (15 wpf) 1 0 0

XY XX XY XX XY XX XY XX XY XX 2 6 0.6

Weight LOEC>102 LOEC> 102 LOEC>51 LOEC>51 LOEC>102 JT: 102 ↑ JT: 51 ↑ LOEC>102 LOEC>51 LOEC>51 3 13 1.5

Length LOEC>102 LOEC>102 LOEC>51 LOEC>51 LOEC>10 2 JT:102 ↑ JT: 13 ↑ LOEC>102 LOEC>51 LOEC>51 4 25 2.6

Survival LOEC>102 LOEC>51 LOEC>102 LOEC>102 LOEC>102 LOEC>102 LOEC>51 LOEC>51 5 51 5.6

Hatch 102 ↓ LOEC>51 6 102 8.5

Papillae 

### D: 51 ↓ LOEC>102 D : 13 ↓ LOEC>51 LOEC>102 LOEC>102 D,JT:102 ↓ LOEC>102 JT:13 ↓ LOEC>51

Vtg 

### D: 51 D: 102 ↑ D : 25 ↑ LOEC>51 D,JT: 51 ↑ LOEC>102 D, JT: 51 ↑ LOEC>102 51 ↑ LOEC>51

Gonad

Phenotype 25 ↑ LOEC>102 25 ↑ LOEC>51 LOEC>102 LOEC>102 13 ↑ LOEC>102 51 ↑ LOEC>51

Fecundity LOEC>102; trend ↓ 102 ↓ 51↓; not by wk

Fertility LOEC>102; trend ↓ 102 ↓ 51↓; e sp wk11

Highest

Conc 102 51 102 102 514tOP F1 Subadult Vitellogenin MED MMT

Concentration (ug/L)Vtg mRNA Relative to Controls

0 6 13 25 51 102 0 100 200 300 400 500

XY

XX

D, JT D, JT D, JT

D, JT

D, JT

4tOP F1 Subadult Vitellogenin MED MMT

Concentration (ug/L)Vtg mRNA Relative to Controls

0 6 13 25 51 102 0 100 200 300 400 500

XY

XX

D, JT D, JT D, JT

D, JT

D, JT4tOP F2 Subadult Vitellogenin MED MMT

Concentration (ug/L)Vtg mRNA Relative to Controls

0 6 13 25 51 102 0 100 200 300 400 500

XY

XX

JT, Tam D, JT

D, JT

4tOP F2 Subadult Vitellogenin MED MMT

Concentration (ug/L)Vtg mRNA Relative to Controls

0 6 13 25 51 102 0 100 200 300 400 500

XY

XX

JT, Tam D, JT

D, JT

D D

D4tOP F1 Subadult SSC MED MMT

Concentration (ug/L)Anal Fin Papillae (#/fin)

0 6 13 25 51 102 0 10 20 30 40 50 60 70 80 90

XY

XX

D,JT D,JT

D,JT

4tOP F1 Subadult SSC MED MMT

Concentration (ug/L)Anal Fin Papillae (#/fin)

0 6 13 25 51 102 0 10 20 30 40 50 60 70 80 90

XY

XX

D,JT D,JT

D,JT

### Original Incorrect Summary Table (Table 1) for 4

- t

- octyphenol NIES (Appendix H, page 46).

Corrected Summary Table (Table 1) for 4

- t

- octyphenol NIES (Appendix H, page 46). 4tOP MMT LOEC Summary 4tOP (ug/L)

F1 F2 F0 F1 F2 Trt Conc S.D.

subadult (8 wpf) subadult (8 wpf) adult (15 wpf) adult (15 wpf) adult (15 wpf) 1 0 na

XY XX XY XX XY XX XY XX XY XX 2 6.25 na

Weight LOEC>100 25 ↑ 3 12.5 na

Length LOEC>100 6.25 ↑ 4 25 na

Survival LOEC>100 ? LOEC>50 ? LOEC>100 LOEC>100 LOEC>50 LOEC>50 5 50 na

Hatch LOEC>100 LOEC>50 6 100 na

Papillae 6.25 ↓ LOEC>100 25 ↓ LOEC>50 50 ↓ LOEC>100 50 ↓ LOEC>50

Vtg 25 ↑ 6.25 ↑ 6.25 ↑ 6.25 ↑

Gonad

Phenotype 100 ? LOEC>100 LOEC>50 LOEC>50

Fecundity 100 ↓ LOEC>50

Fertility 100 ↓ LOEC>50

Highest

Conc 100 50 100 100 50

4tOP MMT LOEC Summary 4tOP (ug/L)

F1 F2 F0 F1 F2 Trt Conc S.D.

subadult (8 wpf) subadult (8 wpf) adult (15 wpf) adult (15 wpf) adult (15 wpf) 1 0 na

XY XX XY XX XY XX XY XX XY XX 2 6.25 na

Weight LOEC>100 LOEC> 50 3 12.5 na

Length LOEC>100 LOEC> 50 4 25 na

Survival LOEC>100 LOEC>50 LOEC>100 LOEC>100 LOEC>50 LOEC>50 5 50 na

Hatch LOEC>100 LOEC>50 6 100 na

Papillae 6.25 ↓ LOEC>100 LOEC>50 LOEC>50 50 ↓ LOEC>100 50 ↓ LOEC>50

Vtg 12.5 ↑ 6.25 ↑ 6.25 ↑ 6.25 ↑

Gonad

Phenotype 100 ? LOEC>100 LOEC>50 LOEC>50

Fecundity 100 ↓ LOEC>50

Fertility 100 ↓ LOEC>50

Highest

Conc 100 50 100 100 50

### Original Incorrect Summary Table (Table 1) for CMP MED (Appendix H, page 83 ).

Corrected Summary Table (Table 1) f or CMP MED (Appendix H, page 83 ). CMP MMT LOEC Summary CMP (ug/L)

F1 F2 F0 F1 F2 Trt Conc S.D.

Subadult (8 wpf) Subadult (8 wpf) Adult (16 wpf) Adult (16 wpf) Adult (16 wpf) 1 0 0

XY XX XY XX XY XX XY XX XY XX 2 21 5

Weight JT:165 ↓ LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 3 43 14

Length JT:165 ↓ LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 4 88 28

Survival LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 5 165 22

Hatch LOEC > 345 LOEC > 345 6 345 74

Papillae LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345

Vtg LOEC > 345 LOEC > 345 LOEC > 345 JT:345 ↓ LOEC > 345 JT:88 ↑ LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345

Gonad Phenotype LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOE C > 345 LOEC > 345 LOEC > 345 LOEC > 345

Fecundity LOEC > 345 LOEC > 345 LOEC > 345

Fertility LO EC > 345 LOEC > 345 LOEC > 345

Highest Conc 345 345 345 345

CMP MMT LOEC Summary CMP (ug/L)

F1 F2 F0 F1 F2 Trt Conc S.D.

Subadult (8 wpf) Subadult (8 wpf) Adult (16 wpf) Adult (16 wpf) Adult (16 wpf) 1 0 0

XY XX XY XX XY XX XY XX XY XX 2 21 5

Weight LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 3 43 14

Length LOEC > 345 LOEC > 345 LOEC > 345 345 ↓ LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 4 88 28

Survival LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 5 165 22

Hatch LOEC > 345 LOEC > 345 6 345 74

Papillae LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345

Vtg LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 JT:88 ↑ LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345

Gonad Phenotype LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345

Fecundity LOEC > 345 LOEC > 345 LOEC > 345

Fertility LOEC > 345 LOEC > 345 LOEC > 345

Highest Conc 345 345 345 345CMP F2 Subadult Vitellogenin MED MMT

Concentration (ug/L)Vtg mRNA Relative to Controls

0 21 43 88 165 345 0 10 20 30 40 50 XY

XX CMP F2 Subadult Vitellogenin MED MMT

Concentration (ug/L)Vtg mRNA Relative to Controls

0 21 43 88 165 345 0 10 20 30 40 50 XY

XX

JTCMP F1 Subadult Weight MED MMT

Concentration (ug/L)Body Weight

0 21 43 88 165 345 0 50 100 150 200 250 300 350 400

XY

XX CMP F1 Subadult Weight MED MMT

Concentration (ug/L)Body Weight

0 21 43 88 165 345 0 50 100 150 200 250 300 350 400

XY

XX

JT JTCMP F1 Subadult Length MED MMT

Concentration (ug/L)Length

0 21 43 88 165 345 0 5 10 15 20 25 30

XY

XX JT JT

CMP F1 Subadult Length MED MMT

Concentration (ug/L)Length

0 21 43 88 165 345 0 5 10 15 20 25 30

XY

XX

### Original Incorrect Summary Table (Table 1) for tamoxifen NIES (Appendix H, page 101).

Tamoxifen MMT LOEC Summary Tamoxifen (ug/L)

F1 F2 F0 F1 Trt Conc S.D.

subadult (54 dpf) subadult (65 dpf) adult adult (92 dpf) 1 0 0

XY XX XY XX XY XX XY XX 2 1.3 0.19

Weight 20↓ 20↓ LOEC>20 20↓ 3 2.5 0.28

Length 20↓ LOEC>20 LOEC>20 20↓ 4 5 0.7

Survival 5 10 1.3

Hatch LOEC>20 LOEC>20 6 20 2.6

SSC 20↓ LOEC>20 1.3↓ LOEC>20 5↑ LOEC>20

Vtg 1.3↑ LOEC>20 1.3↑ 1.3↓ 2.5↑ 5↓

Gonad Phenotype unknown unknown unknown unknown

Fecundity 20↓

Fertility 20↓

Highest Conc 20 20 20 20

Corrected Summary Table (Table 1) for tamoxifen NIES (Appendix H, page 101).

Tamoxifen MMT LOEC Summary Tamoxifen (ug/L)

F1 F2 F0 F1 Trt Conc S.D.

subadult (54 dpf) subadult (65 dpf) adult adult (92 dpf) 1 0 0

XY XX XY XX XY XX XY XX 2 1.3 0.19

Weight LOEC>20 LOEC>20 LOEC>20 LOEC>20 3 2.5 0.28

Length LOEC>20 LOEC>20 LOEC>20 LOEC>20 4 5 0.7

Survival 5 10 1.3

Hatch LOEC>20 LOEC>20 6 20 2.6

SSC 20↓ LOEC>20 1.3↓ LOEC>20 5↑ LOEC>20

Vtg 1.3↑ LOEC>20 2.5 ↑ 1.3↓ 2.5↑ 5↓

Gonad Phenotype unknown unknown unknown unknown

Fecundity 20↓

Fertility 20↓

Highest Conc 20 20 20 20Tamoxifen F2 Subadult (65 dpf) Vitellogenin NIES MMT

Concentration (ug/L)Vtg (ng/mg liver)

0 1.3 2.5 5 10 20 0 200 400 600 800 1000 1200 1400 1600 1800 2000 2200 2400

TD

Du JT JT JT JT JT Du Du Du TD TD TD

TD

Tamoxifen F2 Subadult (65 dpf) Vitellogenin NIES MMT

Concentration (ug/L)Vtg (ng/mg liver)

0 1.3 2.5 5 10 20 0 200 400 600 800 1000 1200 1400 1600 1800 2000 2200 2400

TD

Du JT JT JT JT JT Du Du Du TD TD TD

TD 

### *

*

*

* *

* * * *Tamoxifen F1 Subadult (54 dpf) Weight NIES MMT

Concentration (ug/L)Weight (g)

0 1.3 2.5 5 10 20 0.00 0.02 0.04 0.06 0.08 0.10 0.12 0.14 0.16 0.18 0.20

XX

XY Du TD

JT JT

Tamoxifen F1 Subadult (54 dpf) Weight NIES MMT

Concentration (ug/L)Weight (g)

0 1.3 2.5 5 10 20 0.00 0.02 0.04 0.06 0.08 0.10 0.12 0.14 0.16 0.18 0.20

XX

XY Du TD

JT JTTamoxifen F2 Subadult (65 dpf) Weight NIES MMT

Concentration (ug/L)Weight (g)

0 1.3 2.5 5 10 20 0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40

XX

XY

TD JT

Tamoxifen F2 Subadult (65 dpf) Weight NIES MMT

Concentration (ug/L)Weight (g)

0 1.3 2.5 5 10 20 0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40

XX

XY

TD JTTamoxifen F1 Subadult (54 dpf) Length NIES MMT

Concentration (ug/L)Length (mm)

0 1.3 2.5 5 10 20 0 2 4 6 8 10 12 14 16 18 20 22 24 26

XX

XY Du

Tamoxifen F1 Subadult (54 dpf) Length NIES MMT

Concentration (ug/L)Length (mm)

0 1.3 2.5 5 10 20 0 2 4 6 8 10 12 14 16 18 20 22 24 26

XX

XY DuTamoxifen F2 Subadult (65 dpf) Length NIES MMT

Concentration (ug/L)Length (mm)

0 1.3 2.5 5 10 20 0 5 10 15 20 25 30

XX

XY Du JT

Tamoxifen F2 Subadult (65 dpf) Length NIES MMT

Concentration (ug/L)Length (mm)

0 1.3 2.5 5 10 20 0 5 10 15 20 25 30

XX

XY Du JT

### Original Incorrect Summary Table (Table 1) for trenbolone MED (Appendix H, page 120).

Corrected Summary Table (Table 1) for trenbolone MED (Appendix H, page 118 ). Trenbolone MMT LOEC Summary Trenbolone

(ng/L)

F1 F2 F0 F1 F2 Trt Conc S.D.

Subadult (8 wpf) Subadult (8 wpf) Adult (16 wpf) Adult (16 wpf) Adult (16 wpf) 1 0 0

XY XX XY XX XY XX XY XX XY XX 2 2 0.5

Weight LOEC>84 Du:32 ↓ LOEC>13 LOEC>13 LOEC>84 D,JT:84 ↑ LOEC>84 LOEC>84 LOEC>13 LOEC>13 3 5 1.2

Length LOEC>84 LOEC>84 LOEC>13 LOEC>13 LOEC>84 LOEC>84 LOEC> 84 LOEC>84 LOEC>13 LOEC>13 4 13 2.7

Survival LOEC>84 LOEC>84 LOEC>13 LOEC>13 LOEC>84 LOEC>84 LOEC>84 LOEC>84 LOEC>13 LOEC>13 5 32 4.8

Hatch LOEC>84 LOEC>13 6 84 12.9

Papillae LOEC>84 Du,JT:32 ↑ LOEC>13 LOEC>13 LOEC>84 Du,JT:84 ↑ LOEC>84 Du,JT:84 ↑ LOEC>13 LOEC>13

Vtg LOEC>84 Du,JT:32 ↓ LOEC>13 LOEC>13 LOEC>84 LOEC>84 JT:32 ↓ D:84 ↓ LOEC>13 LOEC>13

Gonad

Phenotype 

### LOEC>84 32 ↑ LOEC>13 LOEC>13 LOEC>84 LOEC>84 LOEC>84 84 ↑ LOEC>13 LOEC>13

Fecundity 84 ↓ 32 ↓ LOEC>13

Fertility 84 ↓ 32 ↓ LOEC>13

Highest Conc 

### 84 13 84 84 13

Trenbolone MMT LOEC Summary Trenbolone

(ng/L)

F1 F2 F0 F1 F2 Trt Conc S.D.

Subadult (8 wpf) Subadult (8 wpf) Adult (16 wpf) Adult (16 wpf) Adult (16 wpf) 1 0 0

XY XX XY XX XY XX XY XX XY XX 2 2 0.5

Weight LOEC>84 D:84 ↓ LOEC>13 LOEC>13 LOEC>84 D,JT:84 ↑ LOEC>84 LOEC>84 LOEC>13 LOEC>13 3 5 1.2

Length LOEC>84 LOEC>84 LOEC>13 LOEC>13 LOEC>84 LOEC>84 LOEC> 84 LOEC>84 LOEC>13 LOEC>13 4 13 2.7

Survival LOEC>84 LOEC>84 LOEC>13 LOEC>13 LOEC>84 LOEC>84 LOEC>84 LOEC>84 LOEC>13 LOEC>13 5 32 4.8

Hatch LOEC>84 LOEC>13 6 84 12.9

Papillae LOEC>84 D :32 ↑ LOEC>13 LOEC>13 LOEC>84 Du,JT:84 ↑ LOEC>84 Du,JT:84 ↑ LOEC>13 LOEC>13

Vtg LOEC>84 D:84 ↓ LOEC>13 LOEC>13 LOEC>84 LOEC>84 JT:32 ↓ D:84 ↓ LOEC>13 LOEC>13

Gonad

Phenotype 

### LOEC>84 32 ↑ LOEC>13 LOEC>13 LOEC>84 LOEC>84 LOEC>84 84 ↑ LOEC>13 LOEC>13

Fecundity 84 ↓ 32 ↓ LOEC>13

Fertility 84 ↓ 32 ↓ LOEC>13

Highest Conc 

### 84 13 84 84 13Trenbolone F1 Subadult Vitellogenin MED MMT

Concentration (ng/L)Vtg mRNA Relative to Controls

0 2 5 13 32 84 0 2 4 6 8 10

XY

XX

Du,JT

Du,JT

Trenbolone F1 Subadult Vitellogenin MED MMT

Concentration (ng/L)Vtg mRNA Relative to Controls

0 2 5 13 32 84 0 2 4 6 8 10

XY

XX

Du,JT

Du,JT 

### *Trenbolone F1 Subadult Weight MED MMT

Concentration (ng/L)Body Weight (mg)

0 2 5 13 32 84 0 50 100 150 200 250 300 350 400

XY

XX Du Du

Trenbolone F1 Subadult Weight MED MMT

Concentration (ng/L)Body Weight (mg)

0 2 5 13 32 84 0 50 100 150 200 250 300 350 400

XY

XX Du Du 

### *

### Original Incorrect Summary Table (Table 1) for prochloraz MED (Appendix H, page 140).

Corrected Summary Table (Table 1) for prochloraz MED (Appendix H, page 137). Prochloraz MMT LOEC Summary Prochloraz ( μ g/L)

F1 F2 F0 F1 F2 Trt Conc S.D.

subadult (8 wpf) subadult (8 wpf) adult (16 wpf) adult (16 wpf) adult (16 wpf) 1 0 0

XY XX XY XX XY XX XY XX XY XX 2 5 1

Weight 9 ↓ 9 ↓ 5 ↓ 9 ↓ LOEC>41 41 ↑ LOEC>25 LOEC>25 LOEC>25 LOEC>25 3 9 2

Length 9 ↓ 9 ↓ 9 ↓ 9 ↓ LOEC>41 9 ↑ 25 ↓ 25 ↓ LOEC>25 LOEC>25 4 17 3

Survival LOEC>25 25 ↓ LOEC>41 LOEC>41 LOEC>25 LOEC>25 LOEC>25 LOEC>25 5 25 4

Hatch 25 ↓ LOEC>25 6 41 3

Papillae 9 ↓ LOEC>25 LOEC>25 LOEC>25 LOEC>41 LOEC>41 LOEC>25 LOEC>25 LOEC>25 LOEC>25

Vtg LOEC>25 9 ↓ LOEC>25 9 ↓

Gonad

Phenotype LOEC>25 LOEC>25 LOEC>25 LOEC>25 LOEC>41 LOEC>41 LOEC>25 LOEC>25 LOEC>25 LOEC>25

Fecundity 41 ↓ LOEC > 25 25 ↓

Fertility 41 ↓ LOEC > 25 25 ↓

Highest Conc 25/41 17/25 41 25 25

Prochloraz MMT LOEC Summary Prochloraz ( μ g/L)

F1 F2 F0 F1 F2 Trt Conc S.D.

subadult (8 wpf) subadult (8 wpf) adult (16 wpf) adult (16 wpf) adult (16 wpf) 1 0 0

XY XX XY XX XY XX XY XX XY XX 2 5 1

Weight 9 ↓ 9 ↓ LOEC>25 9 ↓ LOEC>41 41↑ LOEC>25 LOEC>25 LOEC>25 LOEC>25 3 9 2

Length 9 ↓ 9 ↓ LOEC>25 5 ↓ LOEC>41 9 ↑ 25 ↓ 25 ↓ LOEC>25 LOEC>25 4 17 3

Survival LOEC>25 25 ↓ LOEC>41 LOEC>41 LOEC>25 LOEC>25 LOEC>25 LOEC>25 5 25 4

Hatch 25 ↓ LOEC>25 6 41 3

Papillae 9 ↓ LOEC>25 9 ↓ LOEC>25 LOEC>41 LOEC>41 LOEC>25 LOEC>25 LOEC>25 LOEC>25

Vtg LOEC>25 9 ↓ LOEC>25 9 ↓

Gonad

Phenotype LOEC>25 LOEC>25 LOEC>25 LOEC>25 LOEC>41 LOEC>41 LOEC>25 LOEC>25 LOEC>25 LOEC>25

Fecundity 41 ↓ LOEC > 25 25 ↓

Fertility 41 ↓ LOEC > 25 25 ↓

Highest Conc 25/41 17/25 41 25 25Prochloraz-MED MMT F2 Subadult SSC

Concentration (ug/L)Anal Fin Papillae (#/fin)

0 5 9 17 0 20 40 60 80 100 XY

XX

Individual Fish

Prochloraz-MED MMT F2 Subadult SSC

Concentration (ug/L)Anal Fin Papillae (#/fin)

0 5 9 17 0 20 40 60 80 100 XY

XX

Individual Fish



### D

DProchloraz-MED MMT F2 Subadult Weight

Concentration (ug/L)Body Weight (ug/L)

0 5 9 17 0 50 100 150 200 250 300 350 400

XY

XX

D

D D

D D

Prochloraz-MED MMT F2 Subadult Weight

Concentration (ug/L)Body Weight (ug/L)

0 5 9 17 0 50 100 150 200 250 300 350 400

XY

XX

D

D D

D DProchloraz-MED MMT F2 Subadult Length

Concentration (ug/L)Length (mm)

0 5 9 17 0 5 10 15 20 25 30 35 40

XX

XY JT JT JT

JT

Prochloraz-MED MMT F2 Subadult Length

Concentration (ug/L)Length (mm)

0 5 9 17 0 5 10 15 20 25 30 35 40

XX

XY JT JT JT

JT 

### *

D D

### Original Incorrect Summary Table (Table 1) for vinclozolin MED (Appendix H, page 163).

Corrected Summary Table (Table 1) for vinclozolin MED (Appendix H, page 160). Vinclozolin MMT MED LOEC Summary Vinclolozlin

( μ g/L)

F1 F2 F0 F1 F2 Trt Conc S.D.

Subadult (9 wpf) Subadult (9 wpf) Adult (15 wpf) Adult (15 wpf) Adult 1 0 0

XY XX XY XX XY XX XY XX XY XX 2 17 2

Weight LOEC>136 LOEC>253 LOEC>136 LOEC>136 33 ↑ (JT) 253 ↑ (JT) LOEC>136 70 ↑ (JT) 3 33 3

Length LOEC>136 LOEC>253 LOEC>136 LOEC>136 253 ↑ (JT) LOEC>253 LOEC>136 70 ↑ (JT) 4 70 6

Survival 253 ↓ LOEC>136 LOEC>253 LOEC>253 LOEC>136 LOEC>253 5 136 18

Hatch 253 ↓ need stats LOEC>136 6 253 59

Papillae 17 ↓ (JT) LOEC>253 33 ↓ (JT) LOEC>136 LOEC>253 LOEC>253 LOEC>136 LOEC>253

Vtg LOEC>136 LOEC>253 136↑ (JT) LOEC>136

Gonad

Phenotype LOEC>136 LOEC>253 LOEC>136 LOEC>136 LOEC>136 LOEC>253

Fecundity 17 ↓ (in 3rd week) LOEC>136

Fertility LOEC>253( =fecundity) LOEC>136

Highest

Conc 136/253 136 253 136/253

Vinclozolin MM T MED LOEC Summary Vinclolozlin

( μ g/L)

F1 F2 F0 F1 F2 Trt Conc S.D.

Subadult (9 wpf) Subadult (9 wpf) Adult (15 wpf) Adult (15 wpf) Adult 1 0 0

XY XX XY XX XY XX XY XX XY XX 2 17 2

Weight LOEC>136 LOEC>253 LOEC>136 LOEC>136 33 ↑ (JT) 253 ↑ (JT) LOEC>136 70 ↑ (JT) 3 33 3

Length LOEC>136 LOEC>253 LOEC>136 LOEC>136 253 ↑ (JT) LOEC>253 LOEC>136 70 ↑ (JT) 4 70 6

Survival 253 ↓ LOEC>136 LOEC>253 LOEC>253 LOEC>136 LOEC>253 5 136 18

Hatch 253 ↓ LOEC>136 6 253 59

Papillae 33 ↓ LOEC>253 33 ↓ LOEC>136 LOEC>253 LOEC>253 LOEC>136 LOEC>253

Vtg 3 3↑ LOEC>253 136↑ LOEC>136

Gonad

Phenotype LOEC>136 LOEC>253 LOEC>136 LOEC>136 LOEC>136 LOEC>253

Fecundity 17 ↓ (in 3rd week) LOEC>136

Fertility LOEC>253(=fecundity) LO EC>136

Highest

Conc 136/253 136 253 136/253Vinclozolin F1 Subadult Vitellogenin MED MMT

Concentration (ug/L)Vtg mRNA Relative to Controls

0 17 33 70 136 253 0 500 1000 1500 2000 2500 3000 3500

XY

XX

Vinclozolin F1 Subadult Vitellogenin MED MMT

Concentration (ug/L)Vtg mRNA Relative to Controls

0 17 33 70 136 253 0 500 1000 1500 2000 2500 3000 3500

XY

XX

DVinclozolin F1 Subadult SSC MED MMT

Concentration (ug/L)Anal Fin Papillae (#/fin)

0 17 33 70 136 253 0 20 40 60 80 100 120 140

XY

XX

JT

JT

Vinclozolin F1 Subadult SSC MED MMT

Concentration (ug/L)Anal Fin Papillae (#/fin)

0 17 33 70 136 253 0 20 40 60 80 100 120 140

XY

XX

JT

JT D

### Original Incorrect Summary Table (Table 1) for vinclozolin interlab Lab 1 (Appendix C, page 5).

Vinclozolin MMT Lab 1 LOEC Summary Vinclolozlin ( μ g/L)

F1 F2 F0 F1 Trt Conc S.D.

Subadult (9 wpf) Subadult (9 wpf) Adult (14 wpf) Adult (14 wpf) 1 0

-

Male Female Male Female Male Female Male Female 2 5 1

Weight 82 ↑ (JT) 82 ↑ (JT) LOEC>197 31 ↓ (JT) 3 13 2

Length 4 31 6

Survival LOEC>197 LOEC>197 LOEC>197 LOEC>197 LOEC>197 LOEC>197 5 82 10

Hatch LOEC>197 LOEC>197 6 197 29

Papillae 197 ↓ (JT) LOEC>197 5 ↓ (JT) LOEC>197 31 ↓ (D)

Vtg LOEC>197 LOEC>197 LOEC>197 LOEC>197

Gonad Phenotype LOEC>197 LOEC>197 LOEC>197 LOEC>197 LOEC>197 LOEC>197

Fecundity LOEC>197 LOEC>197

Fertility LOEC>197 LOEC>197

Highest Conc 197 197 197



### Corrected Summary Table (Table 1) for vinclozolin interlab Lab 1 (Appendix C, page 5).

Vinclozolin MMT Lab 1 LOEC Summary Vinclolozlin ( μ g/L)

F1 F2 F0 F1 Trt Conc S.D.

Subadult (9 wpf) Subadult (9 wpf) Adult (14 wpf) Adult (14 wpf) 1 0

-

Male Female Male Female Male Female Male Female 2 5 1

Weight LOEC>197 LOEC>197 LOEC>197 LOEC>197 3 13 2

Length 4 31 6

Survival LOEC>197 LOEC>197 LOEC>197 LOEC>197 LOEC>197 LOEC>197 5 82 10

Hatch LOEC>197 LOEC>197 6 197 29

Papillae 197 ↓ LOEC>197 31 ↓ LOEC>197 31 ↓ (D)

Vtg LOEC>197 LOEC>197 LOEC>197 LOEC>197

Gonad Phenotype LOEC>197 LOEC>197 LOEC>197 LOEC>197 LOEC>197 LOEC>197

Fecundity LOEC>197 LOEC>197

Fertility LOEC>197 LOEC>197

Highest Conc 197 197 197 197Vinclozolin F2 Subadult SSC ABC Labs MMT

Concentration (ug/L)Anal Fin Papillae (#/fin)

0 5 13 31 82 197 0 20 40 60 80 100

Female

Male

JT

JT JT JT JT D

D D D

Vinclozolin F2 Subadult SSC ABC Labs MMT

Concentration (ug/L)Anal Fin Papillae (#/fin)

0 5 13 31 82 197 0 20 40 60 80 100

Female

Male

JT

JT JT JT JT D

D D D Lab 1

Lab 1Vinclozolin F1 Subadult Weight ABC Labs MMT

Concentration (ug/L)Weight (mg)

0 5 13 31 82 197 0 50 100 150 200 250 300 350

Female

Male

JT JT JT

JT

Vinclozolin F1 Subadult Weight ABC Labs MMT

Concentration (ug/L)Weight (mg)

0 5 13 31 82 197 0 50 100 150 200 250 300 350

Female

Male

JT JT JT

JT Lab 1

Lab 1Vinclozolin F2 Subadult Weight ABC Labs MMT

Concentration (ug/L)Weight (mg)

0 5 13 31 82 197 0 50 100 150 200 250 300 350

Female

Male JT JT

JT

Vinclozolin F2 Subadult Weight ABC Labs MMT

Concentration (ug/L)Weight (mg)

0 5 13 31 82 197 0 50 100 150 200 250 300 350

Female

Male JT JT

JT Lab 1

Lab 1

### Original Incorrect Summary Table (Table 1) for vinclozolin Interlab Lab 2 (Appendix C, page 13).

Vinclozolin MMT Lab 2 LOEC Summary Vinclolozlin ( μ g/L)

F1 F2 F0 F1 Trt Conc S.D.

Subadult (9 wpf) Subadult (9 wpf) Adult (14 wpf) Adult (14 wpf) 1 0

-

XY XX XY XX XY XX XY XX 2 12 6

Weight 62 ↑ (JT) 12 ↑ (JT) 62 ↑ (JT) LOEC>360 LOEC>360 LOEC>360 3 25 9

Length 4 62 19

Survival LOEC>360 LOEC>360 LOEC>360 LOEC>360 LOEC>360 LOEC>360 5 155 51

Hatch LOEC>360 LOEC>360 6 360 89

Papillae LOEC>360 LOEC>360 LOEC>360 LOEC>360 LOEC>360 LOEC>360

Vtg LOEC>360 360 ↑ (JT) LOEC>360 LOEC>360

Gonad Phenotype LOEC>360 LOEC>360 LOEC>360 LOEC>360 LOEC>360 LOEC>360

Fecundity LOEC>360

Fertility LOEC>360

Highest Conc 360 360 360 360

Corrected Summary Table (Table 1) for vinclozolin Interlab Lab 2 (Appendix C, page 13).

Vinclozolin MMT Lab 2 LOEC Summary Vinclolozlin ( μ g/L)

F1 F2 F0 F1 Trt Conc S.D.

Subadult (9 wpf) Subadult (9 wpf) Adult (14 wpf) Adult (14 wpf) 1 0

-

XY XX XY XX XY XX XY XX 2 12 6

Weight 360 ↑ 360 ↑ LOEC>360 LOEC>360 LOEC>360 LOEC>360 3 25 9

Length 4 62 19

Survival LOEC>360 LOEC> 360 LOEC>360 LOEC>360 LOEC>360 LOEC>360 5 155 51

Hatch LOEC>360 LOEC>360 6 360 89

Papillae LOEC>360 LOEC>360 LOEC>360 LOEC>360 LOEC>360 LOEC>360

Vtg LOEC>360 LOEC>360 LOEC>360 LOEC>360

Gonad Phenotype LOEC>360 LOEC>360 LOEC>360 LOEC>360 LOEC>360 LOEC>360

Fecundity LOEC>360

Fertility LOEC>360

Highest Conc 360 360 360 360Vinclozolin F1 Subadult Vitellogenin Fort Labs MMT

Concentration (ug/L)Vtg mRNA (copies per ng RNA)

0 12 25 62 155 360 0 2000 4000 6000 8000 10000 12000 14000

XY

XX JT

Vinclozolin F1 Subadult Vitellogenin Fort Labs MMT

Concentration (ug/L)Vtg mRNA (copies per ng RNA)

0 12 25 62 155 360 0 2000 4000 6000 8000 10000 12000 14000

XY

XX JT Lab 2

Lab 2Vinclozolin F1 Weight Fort Labs MMT

Concentration (ug/L)Weight (g)

0 12 25 62 155 360 0.00 0.02 0.04 0.06 0.08 0.10 0.12 0.14 0.16 0.18 0.20 0.22 0.24

XY

XX

JT JT

JT

JT JT JT JT

JT

Vinclozolin F1 Weight Fort Labs MMT

Concentration (ug/L)Weight (g)

0 12 25 62 155 360 0.00 0.02 0.04 0.06 0.08 0.10 0.12 0.14 0.16 0.18 0.20 0.22 0.24

XY

XX

JT JT

JT

JT JT JT JT

JT D D Lab 2

Lab 2Vinclozolin F2 Subadult Weight Fort Labs MMT

Concentration (ug/L)Weight (g)

0 12 25 62 155 360 0.00 0.02 0.04 0.06 0.08 0.10 0.12 0.14 0.16 0.18 0.20 0.22 0.24

XY

XX

JT JT JT

Vinclozolin F2 Subadult Weight Fort Labs MMT

Concentration (ug/L)Weight (g)

0 12 25 62 155 360 0.00 0.02 0.04 0.06 0.08 0.10 0.12 0.14 0.16 0.18 0.20 0.22 0.24

XY

XX

JT JT JT